Mumbai, Nov. 8
RPG Life Sciences Ltd has got a US patent for its novel process of producing Risperidone, a pharmaceutical ingredient used in anti-psychotic medicines.
RPG Life Sciences already has similar patents for Risperidone in the UK, Germany, France, Switzerland and other European markets, the company told the BSE.
Risperidone is an atypical antipsychotic medication used to treat symptoms of schizophrenia. The medication decreases the abnormal excitement in the brain.
The global market for the formulations of Risperidone is estimated to be over $2 billion. The company already sells Risperidone in Spain, India and other developing countries.
It expects to enter other regulated markets when the patent on the product expires.
The product patent expires in Europe in early-2007 and in the US in late 2007 or early 2008, a company official said.
It already supplies the ingredient to other Indian companies. Formerly Searle India, RPG Life Sciences operates in the domestic and international markets with a presence in the therapeutic areas including cardiovascular, central nervous system, anti-diabetic, anti-cancer, immuno-suppressants, anti-infective and anti-inflammatory segments.